Dr. Martens (LON:DOCS) Insider Giles Wilson Purchases 219 Shares of Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson purchased 219 shares of the stock in a transaction on Wednesday, February 11th. The stock was acquired at an average cost of GBX 69 per share, for a total transaction of £151.11.

Giles Wilson also recently made the following trade(s):

• On Tuesday, January 13th, Giles Wilson purchased 192 shares of Dr. Martens stock. The shares were bought at an average cost of GBX 78 per share, for a total transaction of £149.76.
• On Thursday, December 11th, Giles Wilson acquired 197 shares of Dr. Martens stock. The shares were bought at an average price of GBX 76 per share, with a total value of £149.72.

Dr. Martens Stock Performance

Shares of DOCS stock opened at GBX 68.62 on Friday. Dr. Martens plc has a 52-week low of GBX 43.02 and a 52-week high of GBX 100.87. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The stock has a market cap of £663.29 million, a PE ratio of 40.37, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The business has a 50-day simple moving average of GBX 73.90 and a 200-day simple moving average of GBX 82.17.

Dr. Martens (LON:DOCS) last announced its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, equities analysts expect that Dr. Martens plc will post 2.5809394 EPS for the current year.

Analysts Set New Price Targets

DOCS has been the topic of a number of recent analyst reports. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a report on Tuesday, January 27th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Dr. Martens in a research report on Tuesday, February 3rd. Finally, Peel Hunt restated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of GBX 6,000.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.